Compare Autozone Inc (AZO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs GSK plc — how do they compare? Autozone Inc trades at $3,027.46 (market cap $49.67B), while GSK plc trades at $50.35 (market cap $102.60B). The key difference: GSK plc is far larger — about 2.1× Autozone Inc's market cap, and GSK plc pays a 3.57% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| AZO | GSK | |
|---|---|---|
Market Cap | $49.67B | $102.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $61.18 |
52-Week Low | $2.92K | $38.22 |
Enterprise Value | $62.05B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,050.43, down 0.57% on the day, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 EPS of $38.07, beating expectations, but revenue growth has slowed with a net income margin of 12.4% in 2025. Analyst consensus is strongly bullish with a $3,730 price target, though recent insider selling and institutional trimming pose sentiment headwinds.
The outlook remains positive given earnings beats and international expansion, but risks include competitive pressures, margin compression, and macroeconomic sensitivity. Upside is supported by a high GF Score of 84 and DCF valuation above $3,800, yet investors should monitor execution on Q2 2026 earnings and capex efficiency.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
